Olaratumab with doxorubicin for advanced soft tissue sarcoma
NIHR HSRIC
Record ID 32016000403
English
Authors' objectives:
Soft tissue sarcoma is a group of rare cancers that can occur in any part of the body. Sarcoma is usually treated with surgery, but the cancer often returns or spreads to other parts of the body.
Olaratumab is a new drug for the treatment of soft tissue sarcoma that can no longer be treated with surgery. It is delivered directly into the bloodstream through a drip. Some studies have suggested olaratumab may work best in combination with a chemotherapy drug already used for the treatment of this disease called doxorubicin.
If olaratumab is licensed for use in the UK, it could be a new treatment option for patients with advanced soft tissue sarcoma that may improve survival.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/olaratumab-with-doxorubicin-for-advanced-soft-tissue-sarcoma/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Antibodies, Monoclonal
- Doxorubicin
- Sarcoma
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.